Proteus Biomedical, a company that brings together device, pharmaceutical and biotech companies to find answers for cardiac and heart failure patients, has brought in $25.4 million of an anticipated $35 million round of equity, according to a filing with the SEC. Based in Redwood City, Calif., the company is backed the Carlyle Group and Essex Woodlands Venture Partners among others.